increased heart rate semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss Does Semaglutide Increase Heart Rate

Towards tailored obesity treatment choices based on obesity-related complications Ectopic fat deposition in different organs results over time in progressive metabolic dysfunction and the development of organ-specific metabolic complications including T2D, MASLD/MASH and HFpEF [108]

Currently, there are no approved targeted therapies for LVEF-preserved heart failure associated with obesity

The FDA-approved maintenance doses for weight management are 2.4 mg weekly (standard) or 1.7 mg weekly (alternative if higher dose not tolerated)

Breast cancer, diabetes mellitus and glucagon-like peptide-1 receptor toward exploring their possible associations

Per the SmPC and NICE guidance, treatment should be stopped after 12 weeks if the person has not lost at least 5% of their initial body weight